Kilitch Drugs (India) Ltd (KILITCH) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524500 | NSE: KILITCH | Pharmaceuticals & Drugs | Small Cap

Kilitch Drugs(India) Share Price

337.20 -6.05 -1.76%
as on 05-Dec'25 12:17

Kilitch Drugs (India) Ltd (KILITCH) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524500 | NSE: KILITCH | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Kilitch Drugs(India)

Based on:

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Kilitch Drugs (India) stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
18.89
Market Cap:
600 Cr.
52-wk low:
265.5
52-wk high:
490

Is Kilitch Drugs (India) Ltd an attractive stock to invest in?

1. Is Kilitch Drugs (India) Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Kilitch Drugs (India) Ltd is a below average quality company.

2. Is Kilitch Drugs (India) Ltd undervalued or overvalued?

The key valuation ratios of Kilitch Drugs (India) Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Kilitch Drugs (India) Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Kilitch Drugs (India) Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Kilitch Drugs(India):

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Kilitch Drugs (India) Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % -2%-0.3%6%13.8%3.8%4.9%7.8%9.9%10.8%15.5%-
Value Creation
Index
-1.2-1.0-0.60.0-0.7-0.7-0.4-0.3-0.20.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 2128.150.596.460.870105118132182175
Sales YoY Gr.-33.9%79.3%91.1%-37%15.2%50.2%12%11.7%38%-
Adj EPS -1.70.23.58.31.32.95.98.89.21518.2
YoY Gr.-NA1362.5%135.9%-84.2%123.7%100.3%49.1%4.9%63.3%-
BVPS (₹) 86.28790.895.695.4102.7110119.7135.4153.7180.7
Adj Net
Profit
-2.30.34.9132.14.69.413.915.124.632
Cash Flow from Ops. 180.6-1.37.47.36.15.26.1-2.615.2-
Debt/CF from Ops. 01.1-0.61.31.72.43.93.6-12.13.2-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 27.1%24.5%20%38%
Adj EPS NA62.8%36.7%63.3%
BVPS6.6%10%11.8%13.5%
Share Price 22.2% 29.8% 28.5% 1.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-1.90.33.99.21.435.57.57.210.410.9
Op. Profit
Mgn %
-150.511.1171.97.611.314.715.517.116.8
Net Profit
Mgn %
-10.71.29.813.53.46.68.911.811.513.618.2
Debt to
Equity
0000.10.10.10.10.10.10.20.2
Working Cap
Days
536280193173373364299314319285180
Cash Conv.
Cycle
24416386641075939325558104

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 10.90%

Sales growth is growing at healthy rate in last 3 years 19.97%

Net Profit is growing at healthy rate in last 3 years 36.69%

Sales growth is good in last 4 quarters at 21.38%

No data to display

Latest Financials - Kilitch Drugs (India) Ltd.

Standalone Consolidated
TTM EPS (₹) 18.2 15.8
TTM Sales (₹ Cr.) 175 209
BVPS (₹.) 180.7 152
Reserves (₹ Cr.) 298 248
P/BV 1.90 2.26
PE 18.89 21.76
From the Market
52 Week Low / High (₹) 265.50 / 490.00
All Time Low / High (₹) 0.73 / 490.00
Market Cap (₹ Cr.) 600
Equity (₹ Cr.) 17.5
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Kilitch Drugs(India):

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Kilitch Drugs(India) - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Kilitch Drugs(India)

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales212850966170105118132182
Operating Expenses 25294581606594100111150
Manufacturing Costs4434558878
Material Costs9112653363960586692
Employee Cost 33456567810
Other Costs 9101118131520273040
Operating Profit -4-16161511172031
Operating Profit Margin (%) -16.9%-2.0%11.1%16.2%1.9%7.6%10.6%14.7%15.5%17.1%
Other Income 32366455614
Interest 0001111122
Depreciation 2111111112
Exceptional Items 0000000000
Profit Before Tax -2-07205814192341
Tax -0-0151134610
Profit After Tax -2-06154611161831
PAT Margin (%) -9.8%-0.1%12.3%15.3%7.3%8.8%10.0%13.3%13.4%17.2%
Adjusted EPS (₹)-1.5-0.04.49.42.83.96.69.910.719.0
Dividend Payout Ratio (%)0%0%11%5%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 117118127150150163175191223253
Share Capital 13131415151516161616
Reserves 103104114135135147160175206237
Minority Interest0000000000
Debt0119131520223149
Long Term Debt00000000028
Short Term Debt0119131520223121
Trade Payables468581428292647
Others Liabilities 4486248956
Total Liabilities 125128144171173195231250285355

Fixed Assets

Gross Block23242526272836384046
Accumulated Depreciation15161718202122232426
Net Fixed Assets 88788714151620
CWIP 00000001647
Investments 929610110098107117110121121
Inventories33356452415
Trade Receivables16152123172341536283
Cash Equivalents 324436218197
Others Assets 34932424950515861
Total Assets 125128144171173195231250285355

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 181-177656-315
PBT -2-07205814192341
Adjustment 11-1-3-4-0022-6
Changes in Working Capital 200-7-590-6-11-21-11
Tax Paid -00-0-4-2-1-3-4-7-8
Cash Flow From Investing Activity -20-1-2-22-10-5-166-9-41
Capex 0-1-1-2-1-0-8-4-7-47
Net Investments -200-220-0-77-25
Others -1-01-22-9-5-13-11
Cash Flow From Financing Activity -0-061512831116
Net Proceeds from Shares 0030000040
Net Proceeds from Borrowing 00000000028
Interest Paid 000000-1-1-2-2
Dividend Paid -0-0-0-1-200000
Others 0031532849-10
Net Cash Flow -2-020-13-3150-11

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-1.75-0.035.0610.652.973.936.238.598.5113.11
ROCE (%)-2.04-0.266.0113.793.794.917.839.910.7515.49
Asset Turnover Ratio0.170.220.370.610.350.380.490.490.490.57
PAT to CFO Conversion(x)N/AN/A-0.170.471.7510.450.38-0.170.48
Working Capital Days
Receivable Days25220112783121104112146159146
Inventory Days4334191431241511819
Payable Days125150944568100125177152146

Kilitch Drugs (India) Ltd Stock News

Kilitch Drugs (India) Ltd FAQs

The current trading price of Kilitch Drugs(India) on 05-Dec-2025 12:17 is ₹337.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Kilitch Drugs(India) stood at ₹600.0.
The latest P/E ratio of Kilitch Drugs(India) as of 04-Dec-2025 is 18.89.
The latest P/B ratio of Kilitch Drugs(India) as of 04-Dec-2025 is 1.90.
The 52-week high of Kilitch Drugs(India) is ₹490.0 and the 52-week low is ₹265.5.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kilitch Drugs(India) is ₹174.8 ( Cr.) .

About Kilitch Drugs (India) Ltd

Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place.

Kilitch is one of the largest manufacturers of antibacterial parenteral formulations. It is also one of the largest producers of sterile liquid formulations in small volumes in India. Kilitch also boasts of 25 years of quality contract manufacturing service to reputed national and multinational pharmaceutical companies. its sound knowledge about the industry has resulted in the growth of the organizations along with them as a leading contract manufacturing company in the country.

Keeping pace with the increasing demand of its clients for contract manufacturing, Kilitch has added 2 dedicated blocks and is in the process of adding another 3 dedicated fully USFDA / UKMHRA compliant manufacturing facility in Paonta Sahib (North India). All its plants are approved by the local as well as World Health Organization (WHO) for GMP standards. Kilitch has 3 manufacturing facilities spread across India.

Kilitch has over 25 years of experience in product development and manufacturing. It offers a wide spectrum of contract services, providing reliable supply, scientific expertise and bottom line results to meet the development, clinical and commercial outsourcing needs. Kilitch has been engaged in successful tie-ups with over 20 leading pharmaceutical companies -- Ranbaxy Laboratories Limited, Sandoz India Limited, Zydus Cadila, Nicholas Piramal India Limited, USV Limited, Merck Limited to name a few.

In 2010 the company listed its Equity Shares at NSE.

DCGI Approval-- The company has received the DCGI approvals for Ceftriaxone+Tazobactam, Ceftriaxone+Salbactam,Cefipime +Tazobactam and awaiting for approval for the following products, Rabeprazole, Ceftazidime+Tazobactam, Cefoperazone+Tazobactam

Product range of the company includes- Carbapenems, Cephalosporins, Beta - Lactam Antibiotics, Steroids & Hormones, Gastrology, Gastrology, NSAIDs, Anti Malarials

Kilitch has signed an agreement with a US-based pharmaceutical company for manufacturing of its generic molecules for the period of 2 year which started in mid 2008 and would like to expand their business thereon.

Clientele: Sandoz, Ranbaxy, Emcure, Nicholas, Ajanta pharma, Zuventas, Zydus Cadilla, USV, Flamingo Pharma and many others.

You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×